We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum
Read MoreHide Full Article
Key Takeaways
Hologic acquired Endomag to expand its breast surgery localization and tracing solutions.
Endomag's products generated nearly $20M in Hologic's Q3 revenues with higher margins than legacy sales.
Hologic's Interventional Breast segment topped $100M in sales, fueling its growth momentum.
Over the years, Hologic’s (HOLX - Free Report) Breast Health business has evolved, shifting from a heavily capital-focused approach to generating higher recurring revenues. While service revenues now exceed capital sales, the Interventional Breast Solutions segment, which includes Brevera, biopsy needles and markers, is also gradually expanding and contributing more to recurring revenues. This is where Endomagnetics (Endomag) positions itself. It is the Cambridge, UK-based developer of breast cancer surgery technologies, which Hologic acquired in 2024.
The transaction added Endomag’s wireless breast surgery localization and lymphatic tracing solutions, including the Magseed marker, the Magtrace lymphatic tracer and the Sentimag platform, to Hologic’s breast surgery portfolio, providing breast surgeons and radiologists with an expanded range of options and enhanced user experience. With the market transitioning from wire to wireless marking for breast surgery, Hologic is well-positioned to tap into this significant opportunity.
The acquisition was expected to be slightly dilutive to Hologic’s non-GAAP earnings per share in fiscal 2024, break even in 2025 and accretive thereafter. During the second quarter, Hologic began selling Endomag products directly through its sales force in North America, replacing the previous distributor approach. Encouragingly, the business has been exceeding Hologic’s deal model, contributing nearly $20 million of revenues at a very healthy gross margin in the third quarter of fiscal 2025. For context, Endomag carries higher margins than the company’s legacy business.
Hologic topped $100 million in Interventional sales for the first time in the third quarter. The business is gradually becoming a meaningful growth driver, building on the vision the company had put in place years ago for the breast care continuum. With Endomag shifting to Hologic’s organic revenues in the current quarter, it further raises confidence for the Interventional business.
M&A Activity Among Hologic’s Competitors
Medtech giant Boston Scientific (BSX - Free Report) frequently pursues strategic tuck-in M&A in high-growth adjacencies. The sales impact of closed acquisitions contributed 420 basis points, resulting in 17.4% organic revenue growth in the second quarter of 2025. In May, BSX completed the acquisition of the remaining shares of SoniVie Ltd., which expanded its Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for the treatment of hypertension.
Boston Scientific also acquired Intera Oncology, adding its Intera 3000 Hepatic Artery Infusion Pump to administer hepatic artery infusion therapy to treat liver-dominant metastases to the Interventional Oncology portfolio. In April, the company purchased the remaining equity stake in Bolt Medical, bolstering its capabilities to address coronary and peripheral diseases.
Stryker Corp. (SYK - Free Report) , a renowned medtech company, continues to invest in new products and technologies through acquisitions. Earlier this year, the company completed the acquisition of Inari Medical, Inc., a provider of venous thromboembolism (VTE) clot removal solutions without the use of thrombolytic drugs. The addition brought an established peripheral vascular position to Stryker in the fast-growing VTE segment. Last year, the company acquired Vertos Medical, which enhanced its non-surgical solutions for interventionalists addressing chronic lower back pain while broadening its presence in ambulatory surgery centers.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum
Key Takeaways
Over the years, Hologic’s (HOLX - Free Report) Breast Health business has evolved, shifting from a heavily capital-focused approach to generating higher recurring revenues. While service revenues now exceed capital sales, the Interventional Breast Solutions segment, which includes Brevera, biopsy needles and markers, is also gradually expanding and contributing more to recurring revenues. This is where Endomagnetics (Endomag) positions itself. It is the Cambridge, UK-based developer of breast cancer surgery technologies, which Hologic acquired in 2024.
The transaction added Endomag’s wireless breast surgery localization and lymphatic tracing solutions, including the Magseed marker, the Magtrace lymphatic tracer and the Sentimag platform, to Hologic’s breast surgery portfolio, providing breast surgeons and radiologists with an expanded range of options and enhanced user experience. With the market transitioning from wire to wireless marking for breast surgery, Hologic is well-positioned to tap into this significant opportunity.
The acquisition was expected to be slightly dilutive to Hologic’s non-GAAP earnings per share in fiscal 2024, break even in 2025 and accretive thereafter. During the second quarter, Hologic began selling Endomag products directly through its sales force in North America, replacing the previous distributor approach. Encouragingly, the business has been exceeding Hologic’s deal model, contributing nearly $20 million of revenues at a very healthy gross margin in the third quarter of fiscal 2025. For context, Endomag carries higher margins than the company’s legacy business.
Hologic topped $100 million in Interventional sales for the first time in the third quarter. The business is gradually becoming a meaningful growth driver, building on the vision the company had put in place years ago for the breast care continuum. With Endomag shifting to Hologic’s organic revenues in the current quarter, it further raises confidence for the Interventional business.
M&A Activity Among Hologic’s Competitors
Medtech giant Boston Scientific (BSX - Free Report) frequently pursues strategic tuck-in M&A in high-growth adjacencies. The sales impact of closed acquisitions contributed 420 basis points, resulting in 17.4% organic revenue growth in the second quarter of 2025. In May, BSX completed the acquisition of the remaining shares of SoniVie Ltd., which expanded its Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for the treatment of hypertension.
Boston Scientific also acquired Intera Oncology, adding its Intera 3000 Hepatic Artery Infusion Pump to administer hepatic artery infusion therapy to treat liver-dominant metastases to the Interventional Oncology portfolio. In April, the company purchased the remaining equity stake in Bolt Medical, bolstering its capabilities to address coronary and peripheral diseases.
Stryker Corp. (SYK - Free Report) , a renowned medtech company, continues to invest in new products and technologies through acquisitions. Earlier this year, the company completed the acquisition of Inari Medical, Inc., a provider of venous thromboembolism (VTE) clot removal solutions without the use of thrombolytic drugs. The addition brought an established peripheral vascular position to Stryker in the fast-growing VTE segment. Last year, the company acquired Vertos Medical, which enhanced its non-surgical solutions for interventionalists addressing chronic lower back pain while broadening its presence in ambulatory surgery centers.